Salmeterol/fluticasone propionate - Adamis Pharmaceuticals Corporation

Drug Profile

Salmeterol/fluticasone propionate - Adamis Pharmaceuticals Corporation

Alternative Names: APC 5000 DPI; APC-5000; Fluticasone propionate/salmeterol - Adamis Pharmaceuticals; Salmeterol-xinafoate/fluticasone-propionate

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adamis Pharmaceuticals Corporation
  • Class Androstadienes; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 19 Jan 2017 Phase-II development is ongoing in USA
  • 03 Aug 2016 Adamis has European patent for salmeterol/fluticasone propionate using DPI
  • 03 Aug 2016 Adamis received notice of patent allowance for salmeterol/fluticasone propionate using DPI in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top